Skip to content
PubMed This is a summary of 6 peer-reviewed journal articles Updated
Medical Genetics

Genetics and Your Variant: Understanding Your Risk

At a Glance

In ADKH-RRAGD syndrome, the RRAGD variant helps estimate—but cannot determine—heart and kidney disease risk. Some variants are linked to childhood heart muscle disease, while others appear later or mainly affect the kidneys, so specialist monitoring and family counseling remain important.

Understanding the genetics of Kidney tubulopathy-dilated cardiomyopathy syndrome (ADKH-RRAGD) is essential for predicting how the condition might progress and for understanding the risks to your family members. Because this syndrome is caused by changes in the RRAGD gene, your specific “variant”—the exact spot where the genetic code is different—can provide significant clues about your future health [1].

Autosomal Dominant Inheritance

ADKH-RRAGD follows an autosomal dominant pattern of inheritance [2]. This means:

  • One Copy is Enough: You only need one altered copy of the RRAGD gene from one parent to develop the condition.
  • 50% Chance: If a parent has a confirmed pathogenic variant, there is a 50% (1-in-2) chance of passing it on to each child [3].
  • De Novo Mutations: Many people diagnosed with this syndrome are the first in their family to have it. This is called a de novo mutation, meaning the change happened spontaneously during early development and was not inherited from a parent [2]. However, a negative parental blood test does not make the recurrence risk absolutely zero, because mosaicism (where the variant exists in a small fraction of reproductive cells) is possible.

Variant-Specific Disease Behavior

While all known variants of this syndrome involve the kidneys, the impact on the heart varies dramatically depending on which variant you have [1]. Doctors use this information to decide how aggressively to monitor your heart. Because this disease is exceptionally rare, these associations come from a very small number of families. These variants can show incomplete penetrance and variable expressivity. Variant-specific information modifies—but does not replace—clinical monitoring.

High-Risk “Severe Childhood” Variants

The variants S76L (Ser76Leu), I221K (Ile221Lys), and P119R (Pro119Arg) are linked to the most severe forms of the disease [1].

  • Heart Impact: These are often associated with childhood-onset dilated cardiomyopathy [1]. In the first group of children ever studied with this condition, several required heart transplants due to the severity of their heart failure [2].
  • Kidney Impact: Kidney symptoms like low magnesium typically follow in the second decade of life (teenage years), meaning the heart issues often appear first [1].

Adult-Onset Variants

The P88L (Pro88Leu) variant follows a different pattern.

  • Heart Impact: Unlike the childhood variants, P88L is more commonly associated with heart issues that don’t appear until adulthood [1].
  • Kidney Impact: Like others, it involves kidney mineral wasting, but the timeline for both heart and kidney issues is generally later than the high-risk group [1].

Kidney-Focused Variants

The T97P (Thr97Pro) variant has shown the most limited heart involvement to date.

  • Primary Impact: Patients with this variant primarily show signs of kidney tubulopathy (low magnesium and potassium) [4].
  • Cardiac Risk: To date, researchers have not reported heart failure or cardiomyopathy specifically linked to the T97P variant [1]. However, an absence of reported cases does not prove an absence of risk, and regular heart monitoring remains necessary unless your specialist advises otherwise [4].

Prognosis and Screening

Your prognosis—the likely course of your health—is heavily influenced by your genotype. If you have one of the high-risk variants, your care team will likely recommend very frequent echocardiograms (heart ultrasounds) and cardiac MRIs [1].

Family Screening Recommendations:
If you have been diagnosed, your “first-degree” relatives (parents, siblings, and children) should be considered for screening [5]:

  1. Genetic Testing: Targeted testing for a known pathogenic or likely pathogenic familial variant. A Variant of Uncertain Significance (VUS) should not be used to label relatives as affected or unaffected.
  2. Clinical Screening: If genetic testing isn’t available, clinical screening should be individualized by genetics, nephrology, and cardiology rather than a universal blood-test and imaging package [2].
  3. Genetic Counseling: A counselor can help you navigate the complex emotions and choices involved in family testing, including options for future family planning like preimplantation genetic testing [6].

Because the scientific understanding of these variants is still growing, your “provisional” prognosis may change as more patients are identified and studied globally [4].

Common questions in this guide

What can my RRAGD variant tell me about this syndrome?
A pathogenic RRAGD variant identifies the genetic cause of kidney tubulopathy-dilated cardiomyopathy syndrome, but the exact variant can influence how and when heart problems appear. All known variants affect the kidneys, while heart involvement ranges from childhood disease to adult-onset disease or no reported cases so far.
Which RRAGD variants are linked to severe childhood heart disease?
S76L, I221K, and P119R have been associated with severe childhood-onset dilated cardiomyopathy. In reported families, heart failure could occur before kidney mineral wasting, and some children required heart transplantation. These findings come from very few families, so they guide but do not replace individualized monitoring.
What does a P88L RRAGD variant usually mean for heart risk?
P88L has more often been associated with heart problems that begin in adulthood, with kidney mineral wasting also occurring later than in high-risk childhood variants. This pattern is not a guarantee for an individual because the syndrome is rare and can vary among people.
Does a T97P variant rule out heart problems?
T97P has mainly been reported with kidney tubulopathy, including low magnesium and potassium, and no heart failure or cardiomyopathy has been reported specifically with this variant so far. That absence does not prove zero risk, so regular cardiac follow-up should be discussed with a specialist.
How is ADKH-RRAGD inherited, and what is the risk to my children?
ADKH-RRAGD is autosomal dominant, so one disease-causing RRAGD copy is enough to cause the condition. If a parent carries a confirmed pathogenic variant, each child has a 50% chance of inheriting it. Many cases arise de novo, but a negative parental blood test cannot completely eliminate recurrence risk because mosaicism can occur.
Should my parents, siblings, or children have RRAGD testing?
Parents, siblings, and children of a person with a known pathogenic or likely pathogenic RRAGD variant should be considered for targeted testing, even if they have no symptoms. A variant of uncertain significance should not be used by itself to label a relative affected or unaffected. If genetic testing is unavailable, genetics, nephrology, and cardiology teams should individualize clinical screening.
What heart screening may be recommended for ADKH-RRAGD?
People with higher-risk variants may be advised to have frequent echocardiograms (heart ultrasounds) and cardiac MRI. The timing depends on age, variant, symptoms, and previous findings, so a specialist should set the screening schedule.

Get notified when new evidence is published on Kidney tubulopathy-dilated cardiomyopathy syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (6)
  1. 1

    RRAGD-Associated Autosomal Dominant Kidney Hypomagnesemia with Cardiomyopathy: A Review on the Clinical Manifestations and Therapeutic Options.

    Trepiccione F, Sambri I, Ruggiero B, et al.

    Kidney & blood pressure research 2024; (49(1)):637-645 doi:10.1159/000539889.

    PMID: 38901414
  2. 2

    mTOR-Activating Mutations in RRAGD Are Causative for Kidney Tubulopathy and Cardiomyopathy.

    Schlingmann KP, Jouret F, Shen K, et al.

    Journal of the American Society of Nephrology : JASN 2021; (32(11)):2885-2899 doi:10.1681/ASN.2021030333.

    PMID: 34607910
  3. 3

    Prenatal and preimplantation genetic testing for monogenic kidney disorders.

    Knoers NVAM

    Kidney international 2025; (107(2)):255-261 doi:10.1016/j.kint.2024.06.031.

    PMID: 39477068
  4. 4

    Novel RRAGD Variants in Autosomal Dominant Kidney Hypomagnesemia and Therapeutic Perspectives.

    Adella A, Jouret F, Madariaga L, et al.

    Kidney international reports 2025; (10(10)):3640-3655 doi:10.1016/j.ekir.2025.07.035.

    PMID: 41141537
  5. 5

    Genetic Counseling in Kidney Disease: A Perspective.

    Stein Q, Westemeyer M, Darwish T, et al.

    Kidney medicine 2023; (5(7)):100668 doi:10.1016/j.xkme.2023.100668.

    PMID: 37334143
  6. 6

    Preimplantation Genetic Testing for Kidney Disease-Related Genes: A Laboratory's Experience.

    Chaperon JL, Wemmer NM, McKanna TA, et al.

    American journal of nephrology 2021; (52(8)):684-690 doi:10.1159/000518253.

    PMID: 34515037

This page is for informational purposes only and does not constitute medical advice. A genetics professional, nephrologist, or cardiologist can interpret your RRAGD result and recommend screening for you and your family.